Potential Therapeutic Significance of HER-Family in Esophageal Squamous Cell Carcinoma

DOI Web Site PubMed 被引用文献3件 参考文献125件
  • Kono Koji
    Department of Surgery, National University of Singapore, Singapore Cancer Science Institute of Singapore, Singapore
  • Mimura Kousaku
    Department of Surgery, National University of Singapore, Singapore
  • Fujii Hideki
    First Department of Surgery, University of Yamanashi, Yamanashi, Yamanashi, Japan
  • Shabbir Asim
    Department of Surgery, National University of Singapore, Singapore
  • Yong Wei-Peng
    Department of Hematology-Oncology, National University of Singapore, Singapore
  • Jimmy So and
    Department of Surgery, National University of Singapore, Singapore

この論文をさがす

抄録

Despite improvements in surgical techniques and perioperative management and surgery combined with chemotherapy and/or radiotherapy, the prognosis of esophageal squamous cell carcinoma (SCC) at an advanced stage remains poor. Therefore, for esophageal SCC patients, novel therapies such as small molecule inhibitors of tyrosine kinases (TKIs) and humanized monoclonal antibodies (mAbs) are very much needed.Esophageal SCC shows a relatively high incidence of EGFR (33%) and/or HER2(31%) overexpression. Two categories of anti-HER-family-targeting therapies have been in clinical development: small-molecule, HER-family-related TKIs such as Gefitinib,Erlotinib and Lapatinib, and humanized mAbs against the HER family represented by Cetuximab and Trastuzumab. Although there have been very few clinical trials of antiHER-family targeting drugs in esophageal SCC, some in vitro data suggested that the combination of Cetuximab and Trastuzumab could induce synergistic antiproliferative effects and additional antibody-dependent cellular cytotoxicity (ADCC) activities against esophageal SCC cells. A better understanding of the detailed mechanisms involved in EGFR and/or HER2 may help identify new therapeutic targets in esophageal SCC.

収録刊行物

被引用文献 (3)*注記

もっと見る

参考文献 (125)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ